Yoonwon Kook

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Prognostic implication of tumor grade in patients with node-negative breast cancer aged ≤ 50 years with 21-gene recurrence scores of 11-25.

Prognostic implication of tumor grade in patients with node-negative breast cancer aged ≤ 50 years with 21-gene recurrence scores of 11-25.

Journal: International journal of surgery (London, England)

Published: August 14, 2025

Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25).

Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25).

Journal: Journal of breast cancer

Published: August 01, 2025

Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts.

Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts.

Journal: Journal of breast cancer

Published: April 21, 2025

Response to "The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes".

Response to "The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes".

Journal: Clinical breast cancer

Published: February 18, 2025

Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.

Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.

Journal: NPJ breast cancer

Published: January 30, 2025

Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer.

Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer.

Journal: NPJ breast cancer

Published: November 29, 2024

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis.

Journal: Breast cancer research : BCR

Published: November 27, 2024

Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer.

Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer.

Journal: Breast cancer research : BCR

Published: November 26, 2024

Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer.

Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer.

Journal: Cancer treatment and research communications

Published: November 23, 2024

Ovarian Function Suppression in HR-Positive, HER2-Positive Breast Cancer: An Exploratory Analysis of the HERA Trial.

Ovarian Function Suppression in HR-Positive, HER2-Positive Breast Cancer: An Exploratory Analysis of the HERA Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 10, 2024

Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date.

Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date.

Journal: Cancers

Published: September 25, 2024

Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study.

Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study.

Journal: Breast cancer research : BCR

Published: August 16, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026